Aprea Therapeutics Resultados de beneficios anteriores
Pasado controles de criterios 0/6
Aprea Therapeutics has been growing earnings at an average annual rate of 33.2%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been growing at an average rate of 410.9% per year.
Información clave
33.2%
Tasa de crecimiento de los beneficios
54.1%
Tasa de crecimiento del BPA
| Crecimiento de la industria Biotechs | 17.0% |
| Tasa de crecimiento de los ingresos | 410.9% |
| Rentabilidad financiera | -48.1% |
| Margen neto | -1,013.4% |
| Última actualización de beneficios | 30 Jun 2024 |
Actualizaciones de resultados anteriores recientes
No hay actualizaciones
Desglose de ingresos y gastos
Cómo gana y gasta dinero Aprea Therapeutics. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 30 Jun 24 | 1 | -13 | 7 | 0 |
| 31 Mar 24 | 1 | -13 | 7 | 0 |
| 31 Dec 23 | 1 | -14 | 8 | 0 |
| 30 Sep 23 | 1 | -13 | 9 | 16 |
| 30 Jun 23 | 0 | -14 | 6 | 0 |
| 31 Mar 23 | 0 | -109 | 20 | -4 |
| 31 Dec 22 | 0 | -113 | 21 | 0 |
| 30 Sep 22 | 0 | -118 | 22 | 4 |
| 30 Jun 22 | 0 | -123 | 26 | 10 |
| 31 Mar 22 | 0 | -35 | 14 | 21 |
| 31 Dec 21 | 0 | -37 | 14 | 0 |
Ingresos de calidad: APRE is currently unprofitable.
Margen de beneficios creciente: APRE is currently unprofitable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: APRE is unprofitable, but has reduced losses over the past 5 years at a rate of 33.2% per year.
Acelerando crecimiento: Unable to compare APRE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Beneficios vs. Industria: APRE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Rentabilidad financiera
Alta ROE: APRE has a negative Return on Equity (-48.11%), as it is currently unprofitable.